FAQ on Oragenics Inc.'s Q2 2025 Progress and Phase IIa Concussion Trial

What is Oragenics Inc. working on?

Oragenics Inc. is developing brain-targeted therapeutics, including its lead candidate ONP-002, aimed at becoming the first FDA-approved pharmacological treatment for concussion, using proprietary intranasal delivery technology.

Why is Oragenics’ intranasal delivery technology significant?

The technology enables rapid, targeted drug delivery to the brain, bypassing systemic circulation to reduce side effects, with potential applications beyond concussion to acute neurological emergencies and chronic neurodegenerative diseases.

What milestones did Oragenics achieve in Q2 2025?

Oragenics secured Human Research Ethics Committee approval in Australia, appointed Southern Star Research as CRO, and finalized a U.S.-based cGMP manufacturing agreement with Sterling Pharma Solutions.

When are the Phase IIa trials for ONP-002 expected to begin?

Phase IIa trials are expected to launch in Q3 2025.

What is the potential market for nasal drug delivery?

The global nasal drug delivery market is projected to exceed $40 billion by 2030.

How does Oragenics’ approach differ from traditional treatments?

Oragenics’ intranasal delivery platform offers a non-invasive method for targeted brain therapeutics, potentially reducing side effects associated with systemic drug delivery.

Where can I find more information about Oragenics Inc.?

The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN.

What are the broader implications of Oragenics’ work?

Beyond concussion, Oragenics’ technology has the potential to address neurodegenerative diseases, CNS disorders, and other neurological conditions, revolutionizing neurological care.